{"id":70635,"date":"2023-02-22T06:35:00","date_gmt":"2023-02-22T05:35:00","guid":{"rendered":"https:\/\/www.fedaiisf.it\/?p=70635"},"modified":"2023-02-21T19:39:07","modified_gmt":"2023-02-21T18:39:07","slug":"nel-2022-lema-ha-raccomandato-lautorizzazione-allimmissione-in-commercio-di-89-medicinali","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/nel-2022-lema-ha-raccomandato-lautorizzazione-allimmissione-in-commercio-di-89-medicinali\/","title":{"rendered":"In 2022, EMA recommended 89 medicines for marketing authorisation"},"content":{"rendered":"<p>In 2022, EMA recommended 89 medicines for marketing authorisation. Of these, 41 had a new active substance that had never been authorized in the European Union (EU) before. There <img loading=\"lazy\" decoding=\"async\" class=\"wp-image-70638 alignright\" src=\"https:\/\/www.fedaiisf.it\/wp-content\/uploads\/2023\/02\/EMA-illustrazione.png\" alt=\"\" width=\"254\" height=\"208\" srcset=\"https:\/\/www.fedaiisf.it\/wp-content\/uploads\/2023\/02\/EMA-illustrazione.png 486w, https:\/\/www.fedaiisf.it\/wp-content\/uploads\/2023\/02\/EMA-illustrazione-300x246.png 300w\" sizes=\"auto, (max-width: 254px) 100vw, 254px\" \/>r PDF icon overview<a href=\"https:\/\/www.ema.europa.eu\/documents\/report\/human-medicines-highlights-2022_en.pdf\" target=\"_blank\" rel=\"noopener\">key recommendations<\/a> The 2022 data released today includes drug authorization data and a selection of new treatments that represent significant advances in their therapeutic areas.<\/p>\n<p>Public health emergencies remained a key priority for EMA in 2022. The featured paper summarizes the most important recommendations on vaccines and treatments for <a href=\"https:\/\/www.ema.europa.eu\/en\/human-regulatory\/overview\/public-health-threats\/coronavirus-disease-covid-19\/covid-19-latest-updates\" target=\"_blank\" rel=\"noopener\">COVID-19<\/a> and for <a href=\"https:\/\/www.ema.europa.eu\/en\/human-regulatory\/overview\/public-health-threats\/mpox-monkeypox\" target=\"_blank\" rel=\"noopener\">mpox (monkey pox)<\/a>.<\/p>\n<p>Once a medicine is authorized by the European Commission and prescribed to patients, EMA and EU Member States constantly monitor its quality and benefit-risk balance and take regulatory action when necessary. The measures may include a change to the product information, suspension or withdrawal of a medicine or the recall of a limited number of batches. Also included in the document is an overview of some of the most important security recommendations.<\/p>\n<p><a href=\"https:\/\/www.ema.europa.eu\/en\/news\/human-medicines-highlights-2022\" target=\"_blank\" rel=\"noopener\">EMA press release \u2013 16 February 2023<\/a><\/p>\n<p><a href=\"https:\/\/www.ema.europa.eu\/en\/documents\/report\/human-medicines-highlights-2022_en.pdf\" target=\"_blank\" rel=\"noopener\"><strong>EMA. Human Medicines Highlights 2022<\/strong><\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Nel 2022, l&#8217;EMA ha raccomandato l&#8217;autorizzazione all&#8217;immissione in commercio di 89 medicinali. Di questi, 41 avevano un nuovo principio attivo che non era mai stato autorizzato prima nell&#8217;Unione europea (UE). La panoramica dell&#8217;icona PDF delle raccomandazioni chiave del 2022 pubblicate oggi include dati sull&#8217;autorizzazione dei medicinali e una selezione di nuovi trattamenti che rappresentano progressi &hellip;<\/p>","protected":false},"author":4,"featured_media":70639,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[49],"class_list":["post-70635","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizie","tag-aifa"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/70635","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=70635"}],"version-history":[{"count":3,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/70635\/revisions"}],"predecessor-version":[{"id":70640,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/70635\/revisions\/70640"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/70639"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=70635"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=70635"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=70635"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}